| abstract |
REFERRED TO A PYRAZOLO-PYRIDINE DERIVATIVE OF FORMULA (I), WHERE R1 AND R2 ARE H, HALOGEN, CN, C1-C3 ALKYL AND C1-C3 ALCOXY; R3 IS H, HALOGEN, OR C1-C3 ALKYL; R4 IS C3-C5 CYCLOALKYL, C1-C6 ALKYL, C2-C6 ALKENYL, AMONG OTHERS; R5 IS H, HALOGEN, CN, PHENYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 2,6-DIFLUORO-3- (PROPYLSULFONAMIDE) -N- (1H-PIRAZOL [3,4-b] PYRIDIN-5-IL) BENZAMIDE, N- (3-BROMO-1H-PIRAZOLE [3, 4-b] PYRIDIN-5-IL) -2,6-DIFLUORO-3- (PROPYLSULFONAMIDE) BENZAMIDE, 2,6-DIFLUORO-N- (3-PHENYL-1H-PIRAZOL [3,4-b] PYRIDIN-5 -IL) -3- (PROPYLSULFONAMIDE) BENZAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCESS AND A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS INHIBIT RAF KINASE, PARTICULARLY, B-Raf AND ARE USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS SUCH AS CANCER |